Literature DB >> 12780797

Common cytological and cytogenetic features of Epstein-Barr virus (EBV)-positive natural killer (NK) cells and cell lines derived from patients with nasal T/NK-cell lymphomas, chronic active EBV infection and hydroa vacciniforme-like eruptions.

Yu Zhang1, Hiroshi Nagata, Tatsuro Ikeuchi, Hiroyuki Mukai, Michiko K Oyoshi, Ayako Demachi, Tomohiro Morio, Hiroshi Wakiguchi, Nobuhiro Kimura, Norio Shimizu, Kohtaro Yamamoto.   

Abstract

In this study, we describe the cytological and cytogenetic features of six Epstein-Barr virus (EBV)-infected natural killer (NK) cell clones. Three cell clones, SNK-1, -3 and -6, were derived from patients with nasal T/NK-cell lymphomas; two cell clones, SNK-5 and -10, were isolated from patients with chronic active EBV infection (CAEBV); and the other cell clone, SNK-11, was from a patient with hydroa vacciniforme (HV)-like eruptions. An analysis of the number of EBV-terminal repeats showed that the SNK cell clones had monoclonal EBV genomes identical to the original EBV-infected cells of the respective patients, and SNK cells had the type II latency of EBV infection, suggesting that not only the cell clones isolated from nasal T/NK-cell lymphomas but also those isolated from CAEBV and HV-like eruptions had been transformed by EBV to a certain degree. Cytogenetic analysis detected deletions in chromosome 6q in five out of the six SNK cell clones, while 6q was not deleted in four control cell lines of T-cell lineage. This suggested that a 6q deletion is a characteristic feature of EBV-positive NK cells, which proliferated in the diseased individuals. The results showed that EBV-positive NK cells in malignant and non-malignant lymphoproliferative diseases shared common cytological and cytogenetic features.

Entities:  

Mesh:

Year:  2003        PMID: 12780797     DOI: 10.1046/j.1365-2141.2003.04359.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  32 in total

1.  An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection.

Authors:  Chongfeng Xu; Junhong Ai; Qingxun Zhang; Ting Li; Xiaorong Wu; Zhengde Xie; Ziyuan Duan
Journal:  J Vis Exp       Date:  2018-03-30       Impact factor: 1.355

2.  A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy.

Authors:  Christopher P Fox; Tracey A Haigh; Graham S Taylor; Heather M Long; Steven P Lee; Claire Shannon-Lowe; Simon O'Connor; Catherine M Bollard; Javeed Iqbal; Wing C Chan; Alan B Rickinson; Andrew I Bell; Martin Rowe
Journal:  Blood       Date:  2010-07-29       Impact factor: 22.113

3.  [Peripheral NK/T-cell lymphoma].

Authors:  T Rüdiger; A Zettl; P Adam; I Bonzheim; E Geissinger; H K Müller-Hermelink
Journal:  Pathologe       Date:  2007-02       Impact factor: 1.011

4.  Histone deacetylase inhibitor chidamide induces growth inhibition and apoptosis in NK/T lymphoma cells through ATM-Chk2-p53-p21 signalling pathway.

Authors:  Jianan Zhou; Canjing Zhang; Xianxian Sui; Shengxuan Cao; Feng Tang; Shuhui Sun; Songmei Wang; Bobin Chen
Journal:  Invest New Drugs       Date:  2018-03-05       Impact factor: 3.850

5.  Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells.

Authors:  Elina Parri; Heikki Kuusanmäki; Daria Bulanova; Satu Mustjoki; Krister Wennerberg
Journal:  Blood Adv       Date:  2021-04-13

6.  Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008.

Authors:  J I Cohen; H Kimura; S Nakamura; Y-H Ko; E S Jaffe
Journal:  Ann Oncol       Date:  2009-06-10       Impact factor: 32.976

Review 7.  Epstein-barr virus and the pathogenesis of T and NK lymphoma: a mystery unsolved.

Authors:  Lindsay C George; Martin Rowe; Christopher P Fox
Journal:  Curr Hematol Malig Rep       Date:  2012-12       Impact factor: 3.952

8.  BCL-XL inhibition by BH3-mimetic drugs induces apoptosis in models of Epstein-Barr virus-associated T/NK-cell lymphoma.

Authors:  Nenad Sejic; Lindsay C George; Rosemary J Tierney; Catherine Chang; Olga Kondrashova; Ruth N MacKinnon; Ping Lan; Andrew I Bell; Guillaume Lessene; Heather M Long; Andreas Strasser; Claire Shannon-Lowe; Gemma L Kelly
Journal:  Blood Adv       Date:  2020-10-13

9.  Survivin is a prognostic marker and therapeutic target for extranodal, nasal-type natural killer/T cell lymphoma.

Authors:  Li Zhang; Yi Wei; Xiaowei Yan; Na Li; Haolan Song; Li Yang; Yang Wu; Yu-Feng Xi; Hua-Wei Weng; Jian-Hua Li; Edward H Lin; Li-Qun Zou
Journal:  Ann Transl Med       Date:  2019-07

10.  Antineoplastic and anti-inflammatory effects of bortezomib on systemic chronic active EBV infection.

Authors:  Mayumi Yoshimori; Haruna Shibayama; Ken-Ichi Imadome; Fuyuko Kawano; Ayaka Ohashi; Miwako Nishio; Norio Shimizu; Morito Kurata; Shigeyoshi Fujiwara; Ayako Arai
Journal:  Blood Adv       Date:  2021-04-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.